Candel Therapeutics Inc. followed this spring’s positive phase II data in pancreatic cancer with favorable results from a phase III study testing the same drug – viral immunotherapy CAN-2409 – in ...
Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...
Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...
Investor's Business Daily on MSN2d
UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's DrugUniQure stock nearly doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease ...
Med-tech firms raised $23.65 billion in financings through November, an increase of 42% from $16.61 billion raised in the first 11 months of 2023. November’s value totaled $919.99 million, down from ...
Novartis NVS announced positive top-line results from a late-stage study on Fabhalta (iptacopan) in adult patients with ...
Management holds 11th Annual ESG Investor Virtual Event on December 9 at 10 am. NVS ).webcasts.com/starthere.jsp?ei=1689776&tp_key=9312b9a422′ target= ‘_blank’; rel=’nofollow’>Webcast Link Discover ...
Deal-making featured strongly among last week’s news, first with PCT Therapeutics inking an up to 2.9 billion collaboration ...
Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and ...
6d
Analyst Joseph Schwartz from Leerink Partners reiterated a Hold rating on PTC Therapeutics (PTCT – Research Report) and increased the price ...
President-elect Donald Trump hosted the chief executives of Pfizer, Eli Lilly and PhRMA at Mar-a-Lago for a dinner with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback